August 2, 2021 – Abbott (Abbott Park, IL) announced that the U.S. Food and Drug Administration (FDA) has cleared the FreeStyle Libre 2 iOS app for use with compatible iPhones, providing a comprehensive digital offering for its FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system.
Approved for adults and children (4 and older) with diabetes, the new FreeStyle Libre 2 app creates a seamless experience for users and healthcare professionals. The app enables users to get glucose readings directly on their iPhones without the use of a reader. A key benefit of the app is the ability for caregivers to remotely monitor their loved one’s glucose readings and get real-time alarms via the LibreLinkUp app.
Free to download on the iOS App Store soon, the FreeStyle Libre 2 app will offer personalized, up-to-the-minute glucose data for people with diabetes who are using FreeStyle Libre 2 glucose sensors. By scanning the sensor with the FreeStyle Libre 2 app, users will get their current glucose reading and trend arrow which can help them determine how food, exercise and other lifestyle factors impact diabetes management.
With a 14-day wear time, FreeStyle Libre 2 is the longest-lasting iCGM sensor currently on the market, Abbott says.
Integrated features include:
- Optional real-time glucose alarms that automatically alert users when glucose is high or low
- Unsurpassed 14-day accuracy with readings every minute and an eight-hour glucose history, including comprehensive view of trends
- Seamless integration with Abbott’s connected digital health tools – the LibreLinkUp app and LibreView, a secure cloud-based data management platform – allowing users to easily share their glucose readings with healthcare professionals and caregivers.
Abbott has secured partial or full reimbursement for the FreeStyle Libre system in 38 countries, including Canada, France, Germany, Japan, the United Kingdom, and the U.S.